Halpern, JH, Suzuki, J, Huertas, PE, Passie, T. Hallucinogens. In: Addiction Medicine, pp. 1083–1098. Cham, Springer, 2011.Google Scholar

Fantegrossi, WE, Murnane, KS, Reissig, CJ. The behavioral pharmacology of hallucinogens. Biochem Pharmacol 2008;75(1):17–33.Google Scholar

Sinke, C, Halpern, JH, Zedler, M, Neufeld, J, Emrich, HM, Passie, T. Genuine and drug-induced synesthesia: a comparison. Conscious Cogn 2012;21(3):1419–1434.Google Scholar

Jacob, P III, Shulgin, AT. Structure-activity relationships of classic hallucinogens and their analogs. NIDA Res Monogr 1994;146:74–91.Google Scholar

Johnson, M, Richards, W, Griffiths, R. Human hallucinogen research: guidelines for safety. J Psychopharmacol 2008;22(6):603–620. https://doi.org/10.1177/0269881108093587Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 2016;26(8):1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001Google Scholar

Araújo AM, Carvalho F, de Lourdes Bastos M, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 2015 (online). https://doi.org/10.1007/s00204-015-1513-xGoogle Scholar

Tracy, DK, Wood, DM, Baumeister, D. Novel psychoactive substances: types, mechanisms of action, and effects. Br Med J 2017;356:i6848. https://doi.org/10.1136/bmj.i6848Google Scholar

Araújo AM, Carvalho F, de Lourdes Bastos M, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 2015 (online). https://doi.org/10.1007/s00204-015-1513-xGoogle Scholar

Papoutsis I, , Nikolaou P, , Stefanidou M, , Spiliopoulou, C, Athanaselis S. 25B-NBOMe and its precursor 2C-B: modern trends and hidden dangers. Forensic Toxicol 2015;33:1–11. https://doi.org/10.1007/s11419-014-0242-9Google Scholar

Corazza, O, Schifano, F, Farre, M, et al. Designer drugs on the Internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011;6(2):125–129.Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

Winter, JC. Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology 2009;203(2):251–263. https://doi.org/10.1007/s00213-008-1356-8Google Scholar

Corazza, O, Schifano, F, Farre, M, et al. Designer drugs on the Internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011;6(2):125–129.Google Scholar

Halberstadt, AL, Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology 2011;61(3):364–381.Google Scholar

Ray, TS. Psychedelics and the human receptorome. PLoS ONE 2010;5(2):e9019.Google Scholar

Nichols, DE. Hallucinogens. Pharmacol Ther 2004;101(2):131–181.Google Scholar

Frecska, E, Szabo A, , Winkelman MJ, , Luna LE, , McKenna DJ, . A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity. J Neural Transm 2013;120(9):1295–1303.Google Scholar

Carhart-Harris, RL, Erritzoe, D, Williams, T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012;109(6):2138–2143. https://doi.org/10.1073/pnas.1119598109Google Scholar

Psychonaut Wiki Experience: BK-2C-B: Various experiences. https://psychonautwiki.org/wiki/Experience:BK-2C-B_-_Various_experiencesGoogle Scholar

Alatrash, G, Majhail, NS, Pile, JC. Rhabdomyolysis after ingestion of ‘foxy’, a hallucinogenic tryptaminederivative. Mayo Clin Proc 2006;81(4):550–551.Google Scholar

Curtis, B, Kemp, P, Harty, L, Choi, C, Christensen, D. Postmortem identification and quantitation of 2,5-dimethoxy-4-n-propylthiophenethylamine using GC-MSD and GC-NPD. J Anal Toxicol 2003;27(7):493–498.Google Scholar

Kamour, A, James, D, Spears, R, et al. Patterns of presentation and clinical toxicity after reported use of alpha methyltryptamine in the United Kingdom. A report from the UK National Poisons Information Service. Clin Toxicol 2014;52(3):192–197. https://doi.org/10.3109/15563650.2014.885983Google Scholar

Meehan, TJ, Bryant, SM, Aks, SE. Drugs of abuse: the highs and lows of altered mental states in the emergency department. Emerg Med Clin North Am 2010;28(3):663–682. https://doi.org/10.1016/j. emc.2010.03.012Google Scholar

Advisory Council on the Misuse of Drugs (ACMD). Update of the Generic Definition for Tryptamines. Published June 2014. Available at: www.gov.uk/government/uploads/system/uploads/attachment_data/file/318693/UpdateGenericDefinitionTryptamines.pdf [last accessed 21 March 2022].Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. New psychoactive substances in Europe: an update from the EU Early Warning System. Luxembourg, Publications Office of the European Union, 2015.Google Scholar

Gibbons S, , Beharry S, . An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Gibbons S, , Beharry S, . An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Rickli A, , Moning OD, , Hoener MC, , Liechti, ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 2016;26(8):1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001Google Scholar

Palma-Conesa AJ, Ventura M, Galindo L, et al. Something new about something old: a 10-year follow-up on classical and new psychoactive tryptamines and results of analysis. J Psychoactive Drugs 2017 (online). https://doi.org/10.1080/02791072.2017.1320732Google Scholar

Rickli A, , Moning OD, , Hoener MC, , Liechti, ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 2016;26(8):1327–1337. https://doi.org/10.1016/j.euroneuro.2016.05.001Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Papaseit E, Farré M, Pérez-Mañá C, et al. Acute pharmacological effects of 2C-B in humans: an observational study. Front Pharmacol 2018;9:206.Google Scholar

González, D, Torrens, M, Farré, M. Acute effects of the novel psychoactive drug 2C-B on emotions. Biomed Res Int 2015;2015:643878. https://doi.org/10.1155/2015/643878Google Scholar

González, D, Ventura, M, Caudevilla, F, Torrens, M, Farre, M. Consumption of new psychoactive substances in a Spanish sample of research chemical users. Hum Psychopharmacol 2013;28:332–340. https://doi.org/10.1002/hup.2323Google Scholar

Fernández-Calderón, F, Cleland, CM, Palamar, JJ. Polysubstance use profiles among electronic dance music party attendees in New York City and their relation to use of new psychoactive substances. Addict Behav 2017;78:85–93. https://doi.org/10.1016/j.addbeh.2017.11.004Google Scholar

Papaseit E, Farré M, Pérez-Mañá C, et al. Acute pharmacological effects of 2C-B in humans: an observational study. Front Pharmacol 2018;9:206.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Nagai, F, Nonaka, R, Satoh Hasashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007;559:132–137.Google Scholar

Rickli, A, Luethi, D, Reinisch, J, et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 2015;99:546–553.Google Scholar

Braden, MR, Parrish, JC, Naylor, JC, Nichols, DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 2006;70:1956–1964.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine). Joint Reports, Luxembourg, Publications Office of the European Union, 2014. Available at: www.emcdda.europa.eu/system/files/publications/817/TDAS14003ENN_466654.pdf [last accessed 26 April 2022].Google Scholar

Rickli, A, Luethi, D, Reinisch, J, et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 2015;99:546–553.Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2- methoxybenzyl)phenethylamine). Joint Reports, Luxembourg, Publications Office of the European Union, 2014. Available at: www.emcdda.europa.eu/system/files/publications/817/TDAS14003ENN_466654.pdf [last accessed 26 April 2022].Google Scholar

Rickli, A, Luethi, D, Reinisch, J, et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 2015;99:546–553.Google Scholar

Rickli, A, Hoener, MC, Liechti, ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 2015;25:365–376.Google Scholar

Rickli, A, Luethi, D, Reinisch, J, et al. Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 2015;99:546–553.Google Scholar

Krebs, TS, Johansen, P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol 2012;26(7):994–1002.Google Scholar

Lancet, . Reviving research into psychedelic drugs (editorial). Lancet 2006;367:1214.Google Scholar

Sessa, B. Can psychedelics have a role in psychiatry once again. Br J Psychiatry 2005;186:457–458.Google Scholar

Frecska, E, Luna, LE. The adverse effects of hallucinogens from intramural perspective. Neuropsychopharmacol 2006;8:189–200.Google Scholar

Morris, K. Hallucinogen research inspires ‘neurotheology’. Lancet Neurol 2006;5:732.Google Scholar

Gasser, P, Holstein, D, Michel, Y, Doblin, R, Passie, T, Brenneisen, R. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014;202(7):513–520. https://doi.org/10.1097/NMD.0000000000000113Google Scholar

Grob, CS, Danforth, AL, Chopra, GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011;68(1):71–78. https://doi.org/10.1001/archgenpsychiatry.2010.116Google Scholar

Moreno, FA, Wiegand, CB, Taitano, EK, Delgado, PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006;67(11):1735–1740.Google Scholar

Carhart-Harris, RL, Goodwin GM., The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 2017;42:2105–2113.Google Scholar

Garcia-Romeu, A, Kersgaard, B, Addy, PH. Clinical applications of hallucinogens: a review. Exp Clin Psychopharmacol 2016;24:229–268.Google Scholar

Carhart-Harris, RL, Murphy, K, Leech, R, et al. The effects of acutely administered 3,4-methylenedioxymethamphetamine on spontaneous brain function in healthy volunteers measured with arterial spin labeling and blood oxygen level-dependent resting state functional connectivity. Biol Psychiatry 2015;78:554–562.Google Scholar

Carhart-Harris, RL, Wall, MB, Erritzoe, D, et al. The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol 2014;17:527–540.Google Scholar

Carhart-Harris, RL, Bolstridge, M, Rucker, J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016;3:619–627.Google Scholar

Davis, AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse 2019;45(2);161–169. doi.org/10.1080/00952990.2018.1545024Google Scholar

Griffiths, RR, Johnson, MW, Carducci, MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 2016;30:1181–1197.Google Scholar

Ross, S, Bossis, A, Guss, J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016;30:1165–1180.Google Scholar

Gasser, P, Holstein, D, Michel, Y, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis 2014;202:513–520.Google Scholar

Nutt D. Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. J Psychopharmacol 2016;30(12):1163–1164. https://doi.org/10.1177/0269881116675754Google Scholar

Griffiths, RR, Johnson, MW, Carducci, MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 2016;30:1181–1197.Google Scholar

Byock, I. Taking psychedelics seriously. J Palliat Med 2018;21(4):417–421.Google Scholar

Bogenschutz, MP, Forcehimes, AA, Pommy, JA, Wilcox, CE, Barbosa, PC, Strassman, RJ. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29:289–299.Google Scholar

Johnson, MW, Garcia-Romeu, A, Griffiths, RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse 2017;43:55–60.Google Scholar

Bogenschutz MP, , Johnson MW., Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol 2016;64:250–258.Google Scholar

Bogenschutz MP, , Johnson MW., Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol 2016;64:250–258.Google Scholar

Bogenschutz MP, , Johnson MW., Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol 2016;64:250–258.Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2019: Trends and Developments. Luxembourg, Publications Office of the European Union, 2019.Google Scholar

See for example www.bbc.co.uk/news/health-39516345 [last accessed 21 March 2022].Google Scholar

Johnstad PG., Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Studies on Alcohol and Drugs 2018 ;35(1):39–51.Google Scholar

Savulich G, Piercy T, Bruhl AB, et al. Focusing the neuroscience and societal implications of cognitive enhancers. Clin Pharmacol Ther 2017;101(2):170–172.Google Scholar

d’Angelo L-SC, , Savulich G, , Sahakian, BJ. Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure. Br J Pharmacol 2017;174:3257–3267.Google Scholar

Johnstad PG., Powerful substances in tiny amounts: an interview study of psychedelic microdosing. Nordic Studies on Alcohol and Drugs 2018 ;35(1):39–51.Google Scholar

Passie, T, Halpern, JH, Stichtenoth, DO, Emrich, HM, Hintzen, A. The pharmacology of lysergic acid diethylamide: a review. CNS Neurosci Ther 2008;14(4):295–314.Google Scholar

Coppola, M, Mondola, R. Bromo-Dragon Fly: chemistry, pharmacology and toxicology of a benzodifuran derivative producing LSD-like effects. J Addict Res Ther 2012;3(133):2.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery, JM. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Winstock, AR, Kaar, S, Borschmann, R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J Psychopharmacol 2014;28(1):49–54. https://doi.org/10.1177/0269881113513852Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Winstock, AR, Kaar, S, Borschmann, R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J Psychopharmacol 2014;28(1):49–54. https://doi.org/10.1177/0269881113513852Google Scholar

Barsuglia J, , Davis AK, , Palmer, R, et al. Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin. Study Front Psychol 2018;9:2459. doi.org/10.3389/fpsyg.2018.02459Google Scholar

Caudevilla-Gálligo, F, Riba, J, Ventura, M, et al. 4-bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J Psychopharmacol 2012;26(7):1026–1035. https://doi.org/10.1177/0269881111431752Google Scholar

Strassman, R. Human psychopharmacology of LSD, dimethyltryptamine and related compounds. In: A Pletscher, , D Ladewig, , (eds.), Fifty Years of LSD: Current Status and Perspectives of Hallucinogens, pp. 145–174. New York, Parthenon, 1994.Google Scholar

Beharry S., Gibbons S An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Shulgin, A, Shulgin, A. PIHKAL: A Chemical Love Story. Berkeley, CA, Transform Press, 1991.Google Scholar

Corazza, O, Schifano, F, Farre, M, et al. Designer drugs on the Internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011;6(2):125–129.Google Scholar

Strassman, R. Human psychopharmacology of LSD, dimethyltryptamine and related compounds. In: A Pletscher, , D Ladewig, , (eds.), Fifty Years of LSD: Current Status and Perspectives of Hallucinogens, pp. 145–174. New York, Parthenon, 1994.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Beharry S, Gibbons S. An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Corazza O, Schifano F, Farre M, et al. Designer drugs on the Internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011;6(2):125–129.Google Scholar

Caldicott, DG, Bright, SJ, Barratt, MJ. NBOMe – a very different kettle of fish…. Med J Aust 2013;199(5):322–323.Google Scholar

Laing, RR, Beyerstein, BL. Forms of the drug. In: JA Siegel, , (ed.), Hallucinogens: A Forensic Drug Handbook, pp. 39–41. Washington DC, Academic Press, 2003.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Rickli, A, Hoener, MC, Liechti, ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 2015;25:365–376Google Scholar

Lawn, W, Barratt, M, Williams, M, Horne, A, Winstock, A. The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 2014;28(8):780–788.Google Scholar

Bersani, FS, Corazza, O, Albano, G, et al. 25C-NBOme: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. Biomed Res Int 2014;2014:734749. https://doi.org/10.1155/2014/734749Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Hassan Z, Bosch OG, Singh D, et al. Novel psychoactive substances: recent progress on neuropharmacological mechanisms of action for selected drugs. Front Psychiatry 2017 (online). https://doi.org/10.3389/fpsyt.2017.00152Google Scholar

Beharry S, Gibbons S. An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Caudevilla-Gálligo F, Riba J, Ventura M, et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J Psychopharmacol 2012;26(7):1026–1035. https://doi.org/10.1177/0269881111431752Google Scholar

Valento, M, Lebin, J. Emerging drugs of abuse: synthetic cannabinoids, phenylethylamines (2C drugs), and synthetic cathinones. Clin Pediatr Emerg Med 2017;18(3):203–211. https://doi.org/10.1016/j.cpem.2017.07.009Google Scholar

Buffin, J, Roy, A, Williams, H, Winter, A. Part of the Picture: Lesbian, Gay and Bisexual People’s Alcohol and Drug Use in England (2009–2011). Manchester, Lesbian and Gay Foundation, 2012.Google Scholar

Andreasen, MF, Telving, R, Birkler, RI, Schumacher, B, Johannsen, M. A fatal poisoning involving BromoDragonfly. Forensic Sci Int 2009;183(1–3):91–96. https://doi.org/10.1016/j.forsciint.2008.11.001Google Scholar

Lheureux, P, Penaloza, A, Gris, M. Club drugs: a new challenge in clinical toxicology. In: Intensive Care Medicine, pp. 811–820. Cham, Springer, 2003.Google Scholar

McCambridge, J, Winstock, A, Hunt, N, Mitcheson, L. 5-year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res 2006;13(1):57–64.Google Scholar

Williams, RH, Erickson, T. Evaluating hallucinogenic or psychedelic drug intoxication in an emergency setting. Lab Med 2000;31(7):394–401.Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8).Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Shulgin, A, Shulgin, A. TIHKAL: The Continuation. Washington, DC, Transform Press, 1997.Google Scholar

Benschop, A, Urbán, R, Kapitány-Fövény, M, et al. Why do people use new psychoactive substances? Development of a new measurement tool in six European countries. J Psychopharmacol 2020;34(6):600–611. 10.1177/0269881120904951Google Scholar

Global Drug Survey. Drug Pleasure Ratings. Available at: www.globaldrugsurvey.com/past-findings/the-net-pleasure-index-results/ [last accessed 26 April 2022].Google Scholar

Benschop, A, Urbán, R, Kapitány-Fövény, M, et al. Why do people use new psychoactive substances? Development of a new measurement tool in six European countries. J Psychopharmacol 2020;34(6):600–611. 10.1177/0269881120904951Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Papaseit E, Farré M, Pérez-Mañá C, et al. Acute pharmacological effects of 2C-B in humans: an observational study. Front Pharmacol2018;9:206.Google Scholar

Shulgin, AT, Carter, MF. Centrally active phenethylamines. Psychopharm Commun 1975;1:93–98.Google Scholar

C audevilla-Gálligo, F, Riba, J, Ventura, M, et al. 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects. J Psychopharmacol 2012;26(7):1026–1035. https://doi.org/10.1177/0269881111431752Google Scholar

De Boer, D, Gijzels, MJ, Bosman, IJ, Maes, RAA. More data about the new psychoactive drug 2C-B. J Analytic Toxicol 1999;23(3):227–228.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Davis AK, , Barsuglia JP, , Lancelotta, R, Grant, RM, Renn E., The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Psychopharmacology 2018;32(7):779–792. https://doi.org/10.1177/0269881118769063Google Scholar

Griffiths, RR, Richards, WA, McCann, U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 2006;187(3):268–283; discussion 284–292. https://doi.org/10.1007/s00213-006-0457-5Google Scholar

Maclean, KA, Leoutsakos, J-MS, Johnson, MW, et al. Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. JSSR 2012;51(4): 721–737. https://doi.org/10.1111/j.1468-5906.2012.01685.xGoogle Scholar

Barrett, FS, Bradstreet, MP, Leoutsakos, J-MS, et al. The Challenging Experience Questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 2016;30(12):1279–1295. https://doi.org/10.1177/0269881116678781Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Hassan Z, Bosch OG, Singh D, et al. Novel psychoactive substances: recent progress on neuropharmacological mechanisms of action for selected drugs. Front Psychiatry 2017 (online). https://doi.org/10.3389/fpsyt.2017.00152Google Scholar

Timmermann C, , Roseman L, , Williams, L, et al. DMT models the near-death experience. Front Psychol 2018;9:1424.Google Scholar

Beharry S., Gibbons S An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Gable, RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 2007;102(1):24–34.Google Scholar

Studerus, EA. Prediction of psilocybin response in healthy volunteers. PloS ONE 2012;7(2):e30800.Google Scholar

Davis AK, , Barsuglia JP, , Lancelotta, R, Grant, RM, Renn E., The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeODMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption. Psychopharmacology 2018;32(7):779–792. https://doi.org/10.1177/0269881118769063Google Scholar

Garcia-Romeu, A, Griffiths, RR, Johnson, MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev 2015;7(3):157–164.Google Scholar

McGeeney, BE. Cannabinoids and hallucinogens for headache. Headache 2013;53:447–458. https://doi.org/10.1111/head.12025Google Scholar

Sewell, RA, Halpern, JH, Pope, HG. Response of cluster headache to psilocybin and LSD. Neurology 2006;66(12):1920–1922Google Scholar

Karst, M, Halpern, JH, Bernateck, M, Passie, T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia 2010;30(9):1140–1144.Google Scholar

Kast, EC, Collins, VJ. Study of lysergic acid diethylamide as an analgesic agent. Anesth Analg 1964;43(3):285–291.Google Scholar

McCabe, OL. Psychedelic drug crises: toxicity and therapeutics. J Psychedelic Drugs 1977;9:107–121.Google Scholar

Grinspoon, L, Bakalar, JB. Psychedelic Drugs Reconsidered. New York, Basic Books, 1979.Google Scholar

Strassman, RJ. Adverse reactions to psychedelic drugs: a review of the literature. J Nerv Ment Dis 1984;172:577–595.Google Scholar

Klock, JC, Boerner, U, Becker, CE. Coma, hyperthermia and bleeding associated with massive LSD overdose. A report of eight cases. West J Med 1974;120(3):183–188.Google Scholar

Solursh, LP, Clement, WR. Hallucinogenic drug abuse: manifestations and management. Can Med Assoc J 1968;98(8):407.Google Scholar

Riba, J, Barbanoj, MJ. Bringing ayahuasca to the clinical research laboratory. J Psychoactive Drugs 2005;37(2):219–230.Google Scholar

Johnson, MW, Sewell, RA, Griffiths, RR. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers. Drug Alcohol Depend 2012;123(1):132–140.Google Scholar

Lawn, W, Barratt, M, Williams, M, et al. The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample. J Psychopharmacol 2014;28:780–788.Google Scholar

Caldicott, DG, Bright, SJ, Barratt, MJ. NBOMe – a very different kettle of fish. Med J Aust 2013;199:322–323.Google Scholar

Gee P, , Schep LJ, , Jensen BP, , Moore G, Barrington S., Case series: toxicity from 25B-NBOMe – a cluster of N-bomb cases. Clin Toxicol 2016;54(2):141–146. https://doi.org/10.3109/15563650.2015.1115056Google Scholar

Gable, RS. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction 2004;99(6):686–696.Google Scholar

Luethi D, Trachsel D, Hoener MC, Liechti ME. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology 2018;134(Part A):141–148. https://doi.org/10.1016/j.neuropharm.2017.07.012Google Scholar

Wood, DM. Delayed onset of seizures and toxicity associated with recreational use of Bromo-dragon Fly. J Med Toxicol 2009;5(4):226–229.Google Scholar

Peden, NR, Pringle, SD, Crooks, J. The problem of psilocybin mushroom abuse. Hum Exp Toxicol 1982;1(4):417–424.Google Scholar

Kaufman, KR. Anxiety and panic. In: AB Ettinger, , DM Weisbrot, , (eds.), Neurologic Differential Diagnosis: A Case-Based Approach, pp. 22–33. Cambridge, Cambridge University Press, 2014.Google Scholar

Wilson, JM, McGeorge, F, Smolinske, S, Meatherall, R. A foxy intoxication. Forensic Sci Int 2005;148(1):31–36.Google Scholar

Cooles, P. Abuse of the mushroom Panaeolus foenisecii. Br Med J 1980;280(6212):446.Google Scholar

TOXBASE®. LSD. www.toxbase.orgGoogle Scholar

TOXBASE®. Ayahuasca. www.toxbase.orgGoogle Scholar

Hinkelbein, J, Gabel, A, Volz, M, Ellinger, K. Suicide attempt with high-dose ecstasy. Der Anaesthesist 2003;52(1):51–54.Google Scholar

Nielen, RJ, van der Heijden, FM, Tuinier, S, Verhoeven, WM. Khat and mushrooms associated with psychosis. World J Biol Psychiatry 2004;5(1):49–53.Google Scholar

Reich, P, Hepps, RB. Homicide during a psychosis induced by LSD. JAMA 1972;219(7):869–871.Google Scholar

Itokawa, M, Iwata, K, Takahashi, M et al. Acute confusional state after designer tryptamine abuse. Psychiatry Clin Neurosci 2007;61(2):196–199.Google Scholar

Boland, DM, Andollo, W, Hime, GW, Hearn, WL. Fatality due to acute α-methyltryptamine intoxication. J Analytic Toxicol 2005;29(5):394–397.Google Scholar

Fysh, RR, Oon, MCH, Robinson, KN, Smith, RN, White, PC, Whitehouse, MJ. A fatal poisoning with LSD. Forensic Sci Int 1985;8(2):109–113.Google Scholar

Berrens, Z, Lammers, J, White, C. Rhabdomyolysis after LSD ingestion. Psychosomatics 2010;51(4):356. https://doi.org/10.1176/appi.psy.51.4.356Google Scholar

Goforth, HW, Fernandez, F. Acute neurologic effects of alcohol and drugs. Neurol Clin 2012;30(1):277–284.Google Scholar

Gable, RS. Acute toxic effects of club drugs. J Psychoactive Drugs 2004;36(3):303–313.Google Scholar

Gibbons S, Beharry S. An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Gibbons S, Beharry S. An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016;267:25–34.Google Scholar

Luethi D, Trachsel D, Hoener MC, Liechti ME. Monoamine receptor interaction profiles of 4-thio-substituted phenethylamines (2C-T drugs). Neuropharmacology 2018;134(Part A):141–148. https://doi.org/10.1016/j.neuropharm.2017.07.012Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Dean, BV, Stellpflug, SJ, Burnett, AM, Engebretsen, KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013;9(2):172–178. https://doi.org/10.1007/s13181-013-0295-xGoogle Scholar

Tang, MH, Ching, CK, Tsui, MS, Chu, FK, Mak, TW. Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clin Toxicol 2014;52(5):561–565. https://doi.org/10.3109/15563650.2014.909932Google Scholar

Armenian, P, Gerona, RR. The electric Kool-Aid NBOMe test: LC-TOF/MS confirmed 2C-C-NBOMe (25C) intoxication at Burning Man. Am J Emerg Med 2014;32(11):1444.e3–5. https://doi.org/10.1016/j. ajem.2014.04.047Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Gee P, , Schep LJ, , Jensen BP, , Moore G, Barrington S., Case series: toxicity from 25B-NBOMe – a cluster of N-bomb cases. Clin Toxicol 2016;54(2):141–146. https://doi.org/10.3109/15563650.2015.1115056Google Scholar

Kelly, A, Eisenga, B, Riley, B, et al. Case series of 25I-NBOMe exposures with laboratory confirmation. Clin Toxicol 2012;50:702.Google Scholar

Rose, SR, Poklis, JL, Poklis, A. A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol 2013;51:174.Google Scholar

Hill, SL, Doris, T, Gurung, S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol 2013;51:487.Google Scholar

Srisuma, S, Bronstein, AC, Hoyte, CO. NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin Toxicol 2015;11:1–5.Google Scholar

Forrester, MB. NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis. 2014;33:196–201.Google Scholar

Valento, M, Lebin, J. Emerging drugs of abuse: synthetic cannabinoids, phenylethylamines (2C drugs), and synthetic cathinones. Clin Pediatr Emerg Med 2017;18(3):203–211. https://doi.org/10.1016/j.cpem.2017.07.009Google Scholar

Gee, P, Schep, LJ, Jensen, BP, et al. Case series: toxicity from 25B-NBOMe: a cluster of N-bomb cases. Clin Toxicol 2016;54:141–146.Google Scholar

Wood, DM, Sedefov, R, Cunningham, A, Dargan, PI. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol 2015;53:85–92.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Halberstadt, AL. Pharmacology and toxicology of N-Benzylphenethylamine (‘NBOMe’) Hallucinogens. In: M Baumann, , R Glennon, , J Wiley, (eds.), Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences, vol. 32. Cham, Springer, 2017.Google Scholar

Gee, P, Schep, LJ, Jensen, BP, et al. Case series: toxicity from 25B-NBOMe: a cluster of N-bomb cases. Clin Toxicol 2016;54:141–146.Google Scholar

Gee, P, Schep, LJ, Jensen, BP, et al. Case series: toxicity from 25B-NBOMe: a cluster of N-bomb cases. Clin Toxicol 2016;54:141–146.Google Scholar

Forrester, MB. NBOMe designer drug exposures reported to Texas poison centers. J Addict Dis 2014;33:196–201.Google Scholar

Suzuki, J, Dekker, MA, Valenti, ES, et al. Toxicities associated with NBOMe ingestion: a novel class of potent hallucinogens: a review of the literature. Psychosomatics. 2014;56:129–139.Google Scholar

Wood, DM, Sedefov, R, Cunningham, A, et al. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol 2015;53:85–92.Google Scholar

Srisuma, S, Bronstein, AC, Hoyte, CO. NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System. Clin Toxicol 2015;11:1–5.Google Scholar

Poklis, JL, Nanco, CR, Troendle, MM, et al. Determination of 4-bromo2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication. Drug Test Anal 2014;6:764–769.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano, F, Duccio Papanti, G, Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Jebadurai, J, Schifano, F, Deluca, P. Recreational use of 1-(2-naphthyl)-2-(1- pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl) benzofuran (benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Hum Psychopharmacol 2013;28:356–364.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Corazza, O, Schifano, F, Farre, M, et al. Designer drugs on the Internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011;6:125–129.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Dargan, PI, Wood, DM. Novel Psychoactive Substances: Classification, Pharmacology and Toxicology. London, Academic Press/Elsevier, 2013.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Dargan, PI, Wood, DM. Novel Psychoactive Substances: Classification, Pharmacology and Toxicology. London, Academic Press/Elsevier, 2013.Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Dargan, PI, Wood, DM. Novel Psychoactive Substances: Classification, Pharmacology and Toxicology. London, Academic Press/Elsevier, 2013.Google Scholar

Abraham, HD, Aldridge, AM, Gogia, P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996;14(4):285–298.Google Scholar

Twemlow, SW, Bowen, WT. Psychedelic drug-induced psychological crises: attitudes of the ‘crisis therapist’. J Psychoactive Drugs 1979;11(4):331–335.Google Scholar

Vollenweider, FX, Vollenweider-Scherpenhuyzen, MF, Bäbler, A, Vogel, H, Hell, D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998;9(17):3897–3902.Google Scholar

Krebs, TS, Johansen, P-Ø. Psychedelics and mental health: a population study. PloS ONE 2013;8(8):e63972.Google Scholar

Keshavan, MS, Kaneko, Y. Secondary psychoses: an update. World Psychiatry 2013;12(1):4–15.Google Scholar

Miyajima, M, Matsumoto, T, Ito, S. 2C-T-4 intoxication: acute psychosis caused by a designer drug. Psychiatry Clin Neurosci 2008;62(2):243.Google Scholar

Przekop, P, Lee, T. Persistent psychosis associated with Salvia divinorum use. Am J Psychiatry 2009;166(7):832.Google Scholar

Matsumoto, T, Okada, T. Designer drugs as a cause of homicide. Addiction 2006;101(11):1666–1667.Google Scholar

van Amsterdam, J, Opperhuizen, A, van den Brink, W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol 2011;59(3):423–429. https://doi.org/10.1016/j.yrtph.2011.01.006Google Scholar

Vardy, MM, Kay, SR. LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. Arch Gen Psychiatry 1983;40:877–883.Google Scholar

O’Halloran, RL, Lewman, LV. Restraint asphyxiation in excited delirium. Am J Forensic Med Pathol 1993;14(4):289–295.Google Scholar

Jovel, A, Felthous, A, Bhattacharyya, A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J Forensic Sci 2014;59(3):844–846.Google Scholar

Dean, BV, Stellpflug, SJ, Burnett, AM, Engebretsen, KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 2013;9(2):172–178. https://doi.org/10.1007/s13181-013-0295-xGoogle Scholar

Vilke, GM, DeBard, ML, Chan, TC, et al. Excited delirium syndrome (ExDS): defining based on a review of the literature. J Emerg Med 2012;43(5):897–905. https://doi.org/10.1016/j.jemermed.2011.02.017Google Scholar

Gonmori, KYN. Fatal ingestion of magic mushrooms: a case report. Ann Toxicol Anal 2002;14(3):350.Google Scholar

Gahr, M, Plener, PL, Kölle, MA, Freudenmann, RW, Schönfeldt-Lecuona, C. Self-mutilation induced by psychotropic substances: a systematic review. Psychiatry Res 2012;200(2–3):977–983. https://doi.org/10.1016/j.psychres.2012.06.028Google Scholar

Blacha, C, Schmid, MM, Gahr, M, et al. Self-inflicted testicular amputation in first lysergic acid diethylamide use. J Addict Med 2013;7(1):83–84. https://doi.org/10.1097/ADM.0b013e318279737bGoogle Scholar

Attema-de Jonge, ME, Portier, CB, Franssen, EJ. Automutilation after consumption of hallucinogenic mushrooms. Nederlands Tijdschrift voor Geneeskunde 2007;151(52):2869–2872.Google Scholar

Beharry, S, Gibbons, S. An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Sci Int 2016; 267:25–34.Google Scholar

Malleson, N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 1971;118(543):229–230.Google Scholar

Arunotayanun, W, Dalley, JW, Huang, XP, et al. An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging ‘novel psychoactive drugs’. Bioorg Med Chem Lett 2013;23(11):3411–3415. https://doi.org/10.1016/j.bmcl.2013.03.066Google Scholar

Alper, KR, Stajic, M, Gill, JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 2012;57(2):398–412.Google Scholar

Corkery, J, Durkin, E, Elliott, S, Schifano, F, Ghodse, AH. The recreational tryptamine 5-MeO-DALT (N,Ndiallyl-5-methoxytryptamine): a brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39(2):259–62.Google Scholar

Corkery, J, Claridge, H, Loi, B, Goodair, C, Schifano, F. Drug-Related Deaths in the UK: January–December 2012: Annual Report 2013. London, NPSAD, 2014. Available at: www.sgul.ac.uk/about/our-institutes/population-health/documents/NPSAD-Drug-Related-Deaths-January-December-2012.pdf [last accessed 26 April 2022].Google Scholar

Morini L, Bernini M, Vezzoli S, et al. Death after 25C-NBOMe and 25H-NBOMe consumption. Forensic Sci Int 2017;279:e1–6. 10.1016/j.forsciint.2017.08.028Google Scholar

Schifano F, Duccio Papanti G, , Orsolini, L, Corkery JM., Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. Exp Rev Clin Pharmacol 2016;9(7):943–954.Google Scholar

Ninnemann, A, Stuart, GL. The NBOMe series: a novel, dangerous group of hallucinogenic drugs. J Studies Alcohol Drugs 2013;74(6):977.Google Scholar

Gillman, PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13:100–109.Google Scholar

Boyer, EW, Shannon, M. The serotonin syndrome. New Engl J Med 2005;352:1112–1120.Google Scholar

Valento, M, Lebin J. Emerging drugs of abuse: synthetic cannabinoids, phenylethylamines (2C drugs), and synthetic cathinones. Clin Pediatr Emerg Med 2017;18(3):203–211. https://doi.org/10.1016/j.cpem.2017.07.00Google Scholar

Madsen GR, , Petersen TS, , Dalhoff, KP. NBOMe hallucinogenic drug exposures reported to the Danish Poison Information Centre. Dan Med J 2017;64(6):A5386.Google Scholar

Suzuki, J, Dekker, MA, Valenti, ES, et al. Toxicities associated with NBOMe ingestion – a novel class of potent hallucinogens: a review of the literature. Psychosomatics 2015;56:129–139.Google Scholar

Andrabi, S, Greene, S, Moukkadam, N, et al. New drugs of abuse and withdrawal syndromes. Emerg Med Clin North Am 2015;33:779–795.Google Scholar

Gee, P, Schep, LJ, Jensen, BP, et al. Case series: toxicity from 25B-NBOMe: a cluster of N-bomb cases. Clin Toxicol 2016;54:141–146.Google Scholar

Gee, P, Schep, LJ, Jensen, BP, et al. Case series: toxicity from 25B-NBOMe: a cluster of N-bomb cases. Clin Toxicol 2016;54:141–146.Google Scholar

Wood, DM, Sedefov, R, Cunningham, A, et al. Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clin Toxicol 2015;53:85–92.Google Scholar

Suzuki, J, Poklis, JL, Poklis, A. ‘‘My friend said it was good LSD’’: a suicide attempt following analytically confirmed 25I-NBOMe ingestion. J Psychoactive Drugs. 2014;46:379–382.Google Scholar

Gee, P, Schep, LJ, Jensen, BP, et al. Case series: toxicity from 25B-NBOMe: a cluster of N-bomb cases. Clin Toxicol 2016;54:141–146.Google Scholar

Gee, P, Schep, LJ, Jensen, BP, et al. Case series: toxicity from 25B-NBOMe: a cluster of N-bomb cases. Clin Toxicol 2016;54:141–146.Google Scholar

Miller, PL, Gay, GR, Ferris, KC, Anderson, S. Treatment of acute, adverse psychedelic reactions: ‘I’ve tripped and I can’t get down’. J Psychoactive Drugs 1992;24(3):277–279.Google Scholar

O’Brien, CP. Drug addiction and drug abuse. In: Brunton, LL, Lazo, JS, Parker, KL, (eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th ed., pp. 607–627. New York, McGraw-Hill, 2006.Google Scholar

Huesgen, K. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: excited delirium syndrome and sudden death. Emerg Med J 2013;30(11):958–960. https://doi.org/10.1136/emermed-2013-203139.1Google Scholar

Erritzoe, D, Frokjaer, VG, Holst, KK, et al. In vivo imaging of cerebral serotonin transporter and serotonin2a receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) and hallucinogen users. Arch Gen Psychiatry 2011;68(6):562–576. https://doi.org/10.1001/archgenpsychiatry.2011.56Google Scholar

Griffiths, RR, Johnson, MW, Richards, WA, Richards, BD, McCann, U, Jesse, R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 2011;218(4):649–665. https://doi.org/10.1007/s00213-011-2358-5Google Scholar

Nichols, DE. Hallucinogens. Pharmacol Ther 2004;101(2):131–181.Google Scholar

Gillespie, NA, Neale, MC, Prescott, CA, Aggen, SH, Kendler, KS. Factor and item-response analysis DSM-IV criteria for abuse of and dependence on cannabis, cocaine, hallucinogens, sedatives, stimulants and opioids. Addiction 2007;102(6):920–930.Google Scholar

Griffiths, RR, Johnson, MW, Richards, WA, Richards, BD, McCann, U, Jesse, R. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 2011;218(4):649–665. https://doi.org10.1007/s00213-011-2358-5Google Scholar

Strassman, RJ, Qualls, CR, Berg, LM. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans. Biol Psychiatry 1996;39(9):784–795.Google Scholar

Drugs-Forum (various authors). Smoking – DMT tolerance? 2012. Available at: https://drugs-forum.com/threads/dmt-tolerance.176077/ [last accessed 26 April 2022].Google Scholar

Halpern, JH, Pope, HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003;69(2):109–119.Google Scholar

Carhart-Harris, RL, Nutt, DJ. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Substance Use 2010;15(4):283–300.Google Scholar

Baggott, MJ, Coyle, JR, Erowid, E, Erowid, F, Robertson, LC. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 2011;114(1):61–67. https://doi.org/10.1016/j.drugalcdep.2010.09.006Google Scholar

Abraham, H. Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 1983;40:884–889.Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Batra, A, Geppert, M. Hallucinogen persisting perception disorder (HPPD) and flashback – are they identical? J Alcoholism Drug Depend 2013;1:121. https://doi.org/10.4172/ jaldd.1000121Google Scholar

National Institute on Drug Abuse (NIDA). Hallucinogens and Dissociative Drugs, Including LSD, PCP, Ketamine, Psilocybin, Salvia, Peyote, and Dextromethorphan. NIDA, 2014. Available at: https://nida.nih.gov/sites/default/files/rrhalluc.pdf [last accessed 26 April 2022].Google Scholar

Kilpatrick, ZP, Ermentrout, GB. Hallucinogen persisting perception disorder in neuronal networks with adaptation. J Computational Neurosci 2012;32(1):25–53.Google Scholar

Alacorn, RD, Dickinson, WA Dohn, HH. Flashback phenomena: clinical and diagnostic dilemma. J Nerv Ment Dis 1982;170:217–223.Google Scholar

McGee, R. Flashbacks and memory phenomena. A comment on ‘Flashback phenomena: clinical and diagnostic dilemmas. J Nerv Ment Dis 1984;172:273–278.Google Scholar

Stanciu, CN, Penders, TM. Hallucinogen persistent perception disorder induced by new psychoactive substituted phenethylamines; a review with illustrative case. Curr Psychiatry Rev 2016;12(2):221–223. 10.2174/1573400512999160803102947Google Scholar

Martinotti, G, Santacroce, R, PettorrusoM, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Orsolini L, Papanti GD, De Berardis D, et al. The ‘endless trip’ among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 2017;8:240. https://doi.org/10.3389/fpsyt.2017.00240Google Scholar

Martinotti, G, Santacroce, R, PettorrusoM, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Lewis D. Faces of HPPD: hallucinogen persisting perception disorder patient survey results and a descriptive analysis of patient demographics, medical background, drug use history, symptoms, and treatments. Addict DisTreat 2020;19(1):36–51. https://doi.org/10.1097/ADT.0000000000000178Google Scholar

Lerner, AG, Gelkopf, M, Skladman, I, Oyffe, I. Flashback and hallucinogen persisting perception disorder: clinical aspects and pharmacological treatment approach. Isr J Psychiatry Relat Sci 2002;39:92–99.2Google Scholar

Halpern, JH, Pope, HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003;69(2):109–119.Google Scholar

Carhart-Harris, RL, Nutt, DJ. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Subst Use 2010;15(4):283–300.Google Scholar

Baggott, MJ, Coyle, JR, Erowid, E, Erowid, F, Robertson, LC. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 2011;114(1):61–67. https://doi.org/10.1016/j.drugalcdep.2010.09.006Google Scholar

Baggott, MJ, Coyle, JR, Erowid, E, Erowid, F, Robertson, LC. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 2011;114(1):61–67. https://doi.org/10.1016/j.drugalcdep.2010.09.006Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Batra, A, Geppert, M. Hallucinogen persisting perception disorder (HPPD) and flashback – are they identical? J Alcoholism Drug Depend 2013;1:121. https://doi.org/10.4172/jaldd.1000121Google Scholar

Frankel, FH. The concept of flashbacks in historical perspective. Int J Clin Exp Hypn 1994;42(4):321–336.Google Scholar

Puledda, F, Schankin, C, Goadsby, PJ. Visual snow syndrome: a clinical and phenotypical description of 1,100 cases. Neurology 2020;94(6):e564–e574. https://doi.org/10.1212/WNL.0000000000008909Google Scholar

Puledda, F, Schankin, C, Goadsby, PJ. Visual snow syndrome: a clinical and phenotypical description of 1,100 cases. Neurology 2020;94(6):e564–e574. https://doi.org/10.1212/WNL.0000000000008909Google Scholar

Litjens, RPW, Brunt, TM, Alderliefste, G-J, Westerink, RHS. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol 2014;24(8):1309–1323. https://doi.org/10.1016/j.euroneuro.2014.05.008Google Scholar

Halpern, JH, Lerner, AG, Passie, T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In: AL Halberstadt, , FX Vollenweider, , DE Nichols, (eds.), Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol. 36. Berlin, Heidelberg, Springer, 2016.Google Scholar

Abraham, H. Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 1983;40:884–889.Google Scholar

Alacorn, RD, Dickinson WA, Dohn HH. Flashback phenomena: clinical and diagnostic dilemma. J Nerv Ment Dis 1982;170:217–223.Google Scholar

McGee, R. Flashbacks and memory phenomena. A comment on flashback phenomena: clinical and diagnostic dilemmas. J Nerv Ment Dis 1984;172:273–278.Google Scholar

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA, American Psychiatric Publishing, 2013.Google Scholar

Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 2011;114:61–67.Google Scholar

National Institute on Drug Abuse (NIDA). How do hallucinogens (LSD and psilocybin) affect the brain and body? Available at: https://nida.nih.gov/publications/research-reports/hallucinogens-dissociative-drugs/how-do-hallucinogens-lsd-psilocybin-peyote-dmt-ayahuasca-affect-brain-body [last accessed 26 April 2022].Google Scholar

Espiard, ML, Lecardeur, L, Abadie, P, Halbecq, I, Dollfus, S. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Eur Psychiatry 2005; 20(5–6):458–460.Google Scholar

Ikeda, A, Sekiguchi, K, Fujita, K, Yamadera, H, Koga, Y. 5-methoxy-N, N-diisopropyltryptamine-induced flashbacks. Am J Psychiatry 2005;162(4):815.Google Scholar

Lerner, AG, Goodman, C, Rudinski, D, Bleich, A. Benign and time-limited visual disturbances (flashbacks) in recent abstinent high-potency heavy cannabis smokers: a case series study. Isr J Psychiatry Relat Sci 2010;48(1):25–29.Google Scholar

Litjens, RPW, Brunt, TM, Alderliefste, G-J, Westerink, RHS. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol 2014;24(8):1309–1323. https://doi.org/10.1016/j.euroneuro.2014.05.008Google Scholar

Lauterbach, E, Abdelhamid, A, Annandale, JB. Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade. Pharmacopsychiatry 2000;33(1):38–41.Google Scholar

Evans, RW. Reversible palinopsia and the Alice in Wonderland syndrome associated with topiramate use in migraineurs. Headache 2006;46:815–818.Google Scholar

Goldman, S, Galarneau, D, Friedman, R. New onset LSD flashback syndrome triggered by the initiation of SSRIs. Ochsner J 2007;7(1):37–39.Google Scholar

Halpern, JH, Lerner, AG, Passie, T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In: AL Halberstadt, , FX Vollenweider, , DE Nichols, (eds.), Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol. 36. Berlin, Heidelberg, Springer, 2016.Google Scholar

Anderson, L, Lake, H, Walterfang M. The trip of a lifetime: hallucinogen persisting perceptual disorder. Australas Psychiatry 2018;26(1):11–12. https://doi.org/10.1177/1039856217726694Google Scholar

Lerner, AG, Rudinski, D, Bor, O, et al. Flashbacks and HPPD: a clinical-oriented concise review. Isr J Psychiatry Relat Sci 2014;51:296–301.Google Scholar

Shaul, L-R, Feingold D, , Goodman C, , Lerner AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Lerner, AG, Rudinski, D, Bor, O, et al. Flashbacks and HPPD: a clinical-oriented concise review. Isr J Psychiatry Relat Sci 2014;51:296–301.Google Scholar

Shaul, L-R, Feingold D, , Goodman C, , Lerner AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Shaul, L-R, Feingold D, , Goodman C, , Lerner AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Halpern, JH, Lerner, AG, Passie, T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In: AL Halberstadt, , FX Vollenweider, , DE Nichols, (eds.), Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol. 36. Berlin, Heidelberg, Springer, 2016.Google Scholar

Martinotti, G, Santacroce, R, PettorrusoM, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Martinotti, G, Santacroce, R, PettorrusoM, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Halpern, JH, Lerner, AG, Passie, T. A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. In: AL Halberstadt, , FX Vollenweider, , DE Nichols, (eds.), Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences, vol. 36. Berlin, Heidelberg, Springer, 2016.Google Scholar

Lerner, AG, Gelkopf, M, Skladman, I, Oyffe, I. Flashback and hallucinogen persisting perception disorder: Clinical aspects and pharmacological treatment approach. Isr J Psychiatry Relat Sci 2002;39:92–99.Google Scholar

Lerner, AG, Rudinski, D, Bor, O, Flashbacks, Goodman C. and HPPD: a clinical-oriented concise review. Isr J Psychiatry Relat Sci 2014;51:296–302.Google Scholar

Martinotti, G, Santacroce, R, PettorrusoM, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Lerner, AG, Goodman, C, Rudinski, D, Lev-Ran, S. LSD flashbacks—the appearance of new visual imagery not experienced during initial intoxication: two case reports. Isr J Psychiatry Relat Sci 2014;51:307–309.Google Scholar

Lerner, AG, Shufman, E, Kodesh, A, Kretzmer, G, Sigal, M. LSD-induced hallucinogen persisting perception disorder with depressive features treatment with reboxetine. Isr J Psychiatry Relat Sci 2002;39:100–103.Google Scholar

Lerner, AG, Lev-Ran, S. LSD-associated ‘Alice in Wonderland Syndrome’ (AIWS): a hallucinogen persisting perception disorder (HPPD) case report. Isr J Psychiatry Relat Sci 2015;52:67–68.Google Scholar

Shaul, L-R, Feingold D, , Goodman C, , Lerner AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Lerner AG, Rudinski D, Bor O, et al. Flashbacks and HPPD: a clinical oriented concise review. Isr J Psychiatry Relat Sci 2014;51:296–301.Google Scholar

Martinotti, G, Santacroce, R, PettorrusoM, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Lerner, AG, Gelkopf, M, Skladman, I, Oyffe, I. Flashback and hallucinogen persisting perception disorder: clinical aspects and pharmacological treatment approach. Isr J Psychiatry Relat Sci 2002;39:92–99.Google Scholar

Lerner, AG, Rudinski, D, Bor, O, Flashbacks, Goodman C. and HPPD: a clinical-oriented concise review. Isr J Psychiatry Relat Sci 2014;51:296–302.Google Scholar

Lerner, AG, Goodman, C, Rudinski, D, Lev-Ran, S. LSD flashbacks: the appearance of new visual imagery not experienced during initial intoxication: two case reports. Isr J Psychiatry Relat Sci 2014;51:307–309.Google Scholar

Lerner, AG, Shufman, E, Kodesh, A, Kretzmer, G, Sigal, M. LSD-induced hallucinogen persisting perception disorder with depressive features treatment with reboxetine. Isr J Psychiatry Relat Sci 2002;39:100–103.Google Scholar

Shaul, L-R, Feingold D, , Goodman C, , Lerner AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Shaul, L-R, Feingold D, , Goodman C, , Lerner AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Halpern, JH, Pope, HG Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend 2003;69(2):109–119.Google Scholar

Carhart-Harris, RL, Nutt, DJ. User perceptions of the benefits and harms of hallucinogenic drug use: a web-based questionnaire study. J Subst Use 2010;15(4):283–300.Google Scholar

Baggott, MJ, Coyle, JR, Erowid, E, Erowid, F, Robertson, LC. Abnormal visual experiences in individuals with histories of hallucinogen use: a web-based questionnaire. Drug Alcohol Depend 2011;114(1):61–67. https://doi.org/10.1016/j.drugalcdep.2010.09.006Google Scholar

Abraham, H. Visual phenomenology of the LSD flashback. Arch Gen Psychiatry. 1983;40:884–889.Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Batra, A, Geppert, M. Hallucinogen persisting perception disorder (HPPD) and flashback – are they identical? J Alcoholism Drug Depend 2013;1:121. https://doi.org/10.4172/jaldd.1000121Google Scholar

National Institute on Drug Abuse (NIDA). Hallucinogens and Dissociative Drugs, Including LSD, PCP, Ketamine, Psilocybin, Salvia, Peyote, and Dextromethorphan. New South Wales, NIDA, 2014. Available at: https://nida.nih.gov/sites/default/files/rrhalluc.pdf [last accessed 24 March 2022].Google Scholar

Kilpatrick, ZP, Ermentrout, GB. Hallucinogen persisting perception disorder in neuronal networks with adaptation. J Computational Neurosci 2012;32(1):25–53.Google Scholar

Espiard, ML, Lecardeur, L, Abadie, P, Halbecq, I, Dollfus, S. Hallucinogen persisting perception disorder after psilocybin consumption: a case study. Eur Psychiatry 2005;20(5–6):458–460.Google Scholar

Ikeda, A, Sekiguchi, K, Fujita, K, Yamadera, H, Koga, Y. 5-methoxy-N, N-diisopropyltryptamine-induced flashbacks. Am J Psychiatry 2005;162(4):815.Google Scholar

Lerner, AG, Goodman, C, Rudinski, D, Bleich, A. Benign and time-limited visual disturbances (flashbacks) in recent abstinent high-potency heavy cannabis smokers: a case series study. Isr J Psychiatry Relat Sci 2010;48(1):25–29.Google Scholar

Litjens, RPW, Brunt, TM, Alderliefste, G-J, Westerink, RHS. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol 2014;24(8):1309–1323. https://doi.org/0.1016/j.euroneuro.2014.05.008Google Scholar

National Institute on Drug Abuse (NIDA). Hallucinogens and Dissociative Drugs, Including LSD, PCP, Ketamine, Psilocybin, Salvia, Peyote, and Dextromethorphan. New South Wales, NIDA, 2014. Available at: https://nida.nih.gov/sites/default/files/rrhalluc.pdf [last accessed 24 March 2022].Google Scholar

Kilpatrick, ZP, Ermentrout, GB. Hallucinogen persisting perception disorder in neuronal networks with adaptation. J Comput Neurosci 2012;32(1):25–53.Google Scholar

Orsolini L, Duccio Papanti G, De Berardis D, Guirguis A, Corkery JM, Schifano F. The ‘endless trip’ among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 2017;8:240. https://doi.org/10.3389/fpsyt.2017.00240Google Scholar

Orsolini L, Duccio Papanti G, De Berardis D, Guirguis A, Corkery JM, Schifano F. The ‘endless trip’ among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 2017;8:240. https://doi.org/10.3389/fpsyt.2017.00240Google Scholar

Anderson, L, Lake, H, Walterfang M. The trip of a lifetime: hallucinogen persisting perceptual disorder. Australas Psychiatry 2018;26(1):11–12 https://doi.org/10.1177/1039856217726694Google Scholar

Lerner, AG, Rudinski, D, Bor, O, et al. Flashbacks and HPPD: a clinical-oriented concise review. Isr J Psychiatry Relat Sci 2014;51:296–301.Google Scholar

Shaul, L-R, Feingold D, , Goodman C, , Lerner AG. Brief report: comparing triggers to visual disturbances among individuals with positive versus negative experiences of hallucinogen-persisting perception disorder (HPPD) following use of LSD. Am J Addict 2017;26:568–571. https://doi.org/10.1111/ajad.12577Google Scholar

Matefy, RE. Behavior therapy to extinguish spontaneous recurrences of LSD effects: a case study. J Nerv Ment Dis 1973;156:226–231.Google Scholar

Martinotti, G, Santacroce, R, PettorrusoM, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci 2018;8:47. https://doi.org/10.3390/brainsci8030047Google Scholar

Hanck, AL, Scellenken, AF. Hallucinogen persistent perceptive disorder after ecstasy use. Ned Tijdschr Geneeskd 2013;157(24):A5649.Google Scholar

Moskowitz, D. Use of haloperidol to reduce LSD flashbacks. Mil Med 1971;136:754–756.Google Scholar

Thurlow, HJ, Girvin, JP. Use of antiepileptic medication in treating ‘flashbacks’ from hallucinogenic drugs. Can Med Assoc J 1971;105(9):947–948.Google Scholar

Anderson, W, O’Malley, J. Trifluoperazine for the trailing phenomenon. JAMA 1972;220:1244–1245.Google Scholar

Lerner, AG, Skladman, I, Kodesh, A, Sigal, M, Shufman, E. LSD-induced hallucinogen persisting perception disorder treated with clonazepam: two case reports. Isr J Psychiatry Relat Sci 2001;38(2):133–136.Google Scholar

Abraham, HD. Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 1983;40:884–889. https://doi.org/10.1001/archpsyc.1983.01790070074009Google Scholar

Abraham, HD. LSD flashbacks (Letters to the editor/In reply). Arch Gen Psychiatry 1984;41:632.Google Scholar

Young, CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 1997;58:85.Google Scholar

Lerner, AG, Oyffe, I, Issacs, G, Mircea, M. Naltrexone treatment of hallucinogen persisting perception disorder. Am J Psychiatry 1997;154:437.Google Scholar

Lerner, AG, Finkel, B, Oyffe, I, Merenzon, I, Sigal, M. Clonidine treatment for hallucinogen persisting perception disorder. Am J Psychiatry 1998;155:1460.Google Scholar

Lerner, AG, Gelkopf, M, Oyffe, I, et al. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. Int Clin Psychopharmacol 2000;15:35–37.Google Scholar

Aldurra, G, Crayton, JW. Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. J Clin Psychopharmacol 2001;2:343–344.Google Scholar

Young, CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 1997;58:85. https://doi.org/10.4088/JCP.v58n0206aGoogle Scholar

Lerner, AG, Skladman, I, Kodesh, A, Sigal, M, Shufman, E. LSD-induced hallucinogen persisting perception disorder treated with clonazepam: two case reports. Isr J Psychiatry Relat Sci 2001;38(2):133–136.Google Scholar

Lerner, AG, Gelkopf, M, Skladman, I, Rudinski, D, Nachshon, H, Bleich, A. Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Int Clin Psychopharmacol 2003;18(2):101–105. https://doi.org10.1097/00004850-200303000-00007Google Scholar

Lerner, AG, Shufman, E, Kodesh, A, Kretzmer, G, Sigal, M. LSD-induced hallucinogen persisting perception disorder with depressive features treated with reboxetine: case report. Isr J Psychiatry Relat Sci (2002) 39(2):100–3.Google Scholar

Feeney, K. Revisiting Wasson’s soma: exploring the effects of preparation on the chemistry of Amanita muscaria. J Psychoactive Drugs 2010;42(4):499–506.Google Scholar

Subramanian, N, Doran, M. Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report. Ir J Psychol Med 2013;31(1):47–49. https://doi.org/10.1017/ipm.2013.59Google Scholar

Orsolini L, Duccio Papanti G, De Berardis D, Guirguis A, Corkery JM, Schifano F. The ‘endless trip’ among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review. Front Psychiatry 2017;8:240. https://doi.org/10.3389/fpsyt.2017.00240Google Scholar

Subramanian, N, Doran, M. Improvement of hallucinogen persisting perception disorder (HPPD) with oral risperidone: case report. Ir J Psychol Med 2013;31(1):47–49. https://doi.org/10.1017/ipm.2013.59Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Geppert, M. Hallucinogen-persisting perception disorder. Ther Adv Psychopharmacol 2012;2(5):199–205. https://doi.org/10.1177/2045125312451270Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Batra, A, Geppert, M. Hallucinogen persisting perception disorder (HPPD) and flashback are they identical? J Alcohol Drug Depend 2013;1:4. https://doi.org/10.4172/1000121Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Batra, A, Geppert, M. Hallucinogen persisting perception disorder (HPPD) and flashback are they identical? J Alcohol Drug Depend 2013;1:4. https://doi.org/10.4172/1000121Google Scholar

Hermle, L, Simon, M, Ruchsow, M, Geppert, M. Hallucinogen-persisting perception disorder. Ther Adv Psychopharmacol 2012;2(5):199–205. https://doi.org/10.1177/2045125312451270Google Scholar

Abraham, HD, Mamen, A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996;16(3):238–241. https://doi.org/10.1097/00004714-199606000-00008Google Scholar

Morehead, DB. Exacerbation of hallucinogen-persisting perception disorder with risperidone. J Clin Psychopharmacol 1997;17:327–328.Google Scholar

Markel, H, Lee, A, Holmes, RD, Domino, EF. LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 1994;125:817–819.Google Scholar